Detection and evaluation of a drug safety signal concerning pancreatic cancer: Lessons from a joint approach of three European biologics registers

Rheumatology

Volumn 50, Issue 1, 2011, Pages 146-151

  Strangfeld, Anja ^a   Hyrich, Kimme ^b   Askling, Johan ^c   Arkema, Elizabeth ^c   Davies, Rebecca ^b   Listing, Joachim ^a   Neovius, Martin ^c   Simard, Julia ^c   Symmons, Deborah ^b   Watson, Kath ^b   Zink, Angela ^a,d  

^a Leibniz Institute   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

British society for rheumatology biologics register; Collaborative analyses; German biologics register; Leflunomide; Malignancies; Pharmacoepidemiology; Pharmacovigilance; Swedish rheumatology register

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRITISH SOCIETY OF RHEUMATOLOGY BIOLOGICS REGISTER; CALCULATION; CANCER INCIDENCE; CANCER REGISTRY; CONTROLLED STUDY; DEATH CERTIFICATE; DRUG DETERMINATION; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; FEMALE; GERMAN BIOLOGICS REGISTER; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PANCREAS CANCER; PHYSICIAN; PRIORITY JOURNAL; REGISTER; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS OBSERVATION OF BIOLOGIC THERAPY; SEX DIFFERENCE; SIGNAL TRANSDUCTION; STANDARDIZED INCIDENCE RATIO; SWEDEN; SWEDISH RHEUMATOLOGY REGISTER; UNITED KINGDOM;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GERMANY; GREAT BRITAIN; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; REGISTRIES; RISK FACTORS; SWEDEN;

EID: 79951714147     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq301     Document Type: Article

References (8)

1. Strangfeld A, Listing J, Herzer P et al. A six-fold increase in the incidence of pancreatic carcinoma in rheumatoid arthritis patients receiving leflunomide. Ann Rheum Dis 2009;68(Suppl. 3):584.
2. Strangfeld A, Listing J, Herzer P et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
3. Hyrich KL, Watson KD, Isenberg DA, Symmons DP. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology 2008;47:1441-3.
4. Askling J, van Vollenhoven RF, Granath F et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60: 3180-9.
5. Office for National Statistics. Cancer statistics: registration series. http://www.statistics.gov.uk/statbase/Product.asp?vlnk=8843 (23 March 2010, date last accessed).
6. Robert-Koch-Institut. Incidence rates of malignancies in Germany. http://www.rki.de/cln_169/nn_204124/DE/Content/GBE/DachdokKrebs/Datenbankabfragen/Neuerkrankungen/neuerkrankungen__node.html?__nnn=true (26 March 2010, date last accessed).
7. The National Board of Health and Welfare. Cancer incidence in Sweden 2005. http://www.socialstyrelsen.se/uppfoljning/statistik/statistikefteramne/cancer (31 March 2010, date last accessed).
8. Sokka T, Kautiainen H, Toloza S et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007;66:1491-6.